**Supplementary Table 1.** Adverse events (AEs) detail

|  |  |
| --- | --- |
|  | **All-bari-RA Japanese** N=514 |
| ***TEAEs in ≥ 2% of Patients from All-bari-RA set, n (EAIR)***  |  |
| Nasopharyngitis | 184 (21.6) |
| Blood creatine phosphokinase increased | 56 (6.6) |
| Hepatic function abnormal | 55 (6.5) |
| Herpes zoster | 54 (6.3) |
| Influenza | 39 (4.6) |
| Pharyngitis | 38 (4.5) |
| Hyperlipidaemia  | 36 (4.2) |
| Upper respiratory tract inflammation | 33 (3.9) |
| Constipation | 32 (3.8) |
| Bronchitis | 30 (3.5) |
| Contusion | 30 (3.5) |
| Dental caries | 28 (3.3) |
| Lymphopenia | 28 (3.3) |
| Hypercholesterolaemia | 27 (3.2) |
| Hypertension | 27 (3.2) |
| Stomatitis | 27 (3.2) |
| Upper respiratory tract infection | 26 (3.1) |
| Lymphocyte count decreased | 25 (2.9) |
| Gastroenteritis | 23 (2.7) |
| Back pain | 22 (2.6) |
| Dyslipidaemia | 22 (2.6) |
| Nausea | 21 (2.5) |
| Rash | 21 (2.5) |
| Anaemia | 20 (2.3) |
| Cystitis | 20 (2.3) |
| Headache | 20 (2.3) |
| Tooth extraction | 20 (2.3) |
| Abdominal discomfort | 18 (2.1) |
| Gastrooesophageal reflux disease | 18 (2.1) |
| Hepatic steatosis | 17 (2.0) |
| Muscle spasms | 17 (2.0) |
| Alanine aminotransferase increased | 16 (1.9) |
| Cough | 16 (1.9) |
| Eczema | 16 (1.9) |
| Periodontitis | 16 (1.9) |
| Aspartate aminotransferase increased | 15 (1.8) |
| Liver function test abnormal  | 15 (1.8) |
| Abdominal pain upper | 14 (1.6) |
| Chronic gastritis | 14 (1.6) |
| Leukopenia | 14 (1.6) |
| Diarrhoea | 13 (1.5) |
| Endoscopy upper gastrointestinal tract | 13 (1.5) |
| Oral herpes | 13 (1.5) |
| Osteoporosis | 13 (1.5) |
| Dizziness | 12 (1.4) |
| Dry eye | 12 (1.4) |
| Lumbar spinal stenosis | 12 (1.4) |
| Spinal osteoarthritis | 12 (1.4) |
| Tinea pedis | 12 (1.4) |
| Acne | 11 (1.3) |
| Insomnia | 11 (1.3) |
| Pneumonia | 11 (1.3) |
| ***Temporary Interruption Due to AE by system organ classes, n (EAIR)*** |  |
| Infections and infestations | 126 (14.8) |
| Investigations | 24 (2.8) |
| Blood and lymphatic system disorders | 16 (1.9) |
| Respiratory, thoracic and mediastinal disorders | 15 (1.8) |
| Gastrointestinal disorders | 11 (1.3) |
| Surgical and medical procedures | 8 (0.9) |
| Injury, poisoning and procedural complications | 7 (0.8) |
| General disorders and administration site conditions | 6 (0.7) |
| Hepatobiliary disorders | 6 (0.7) |
| Musculoskeletal and connective tissue disorders | 4 (0.5) |
| Skin and subcutaneous tissue disorders | 4 (0.5) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3 (0.4) |
| Cardiac disorders | 2 (0.2) |
| Eye disorders | 2 (0.2) |
| Endocrine disorders | 1 (0.1) |
| Renal and urinary disorders | 1 (0.1) |
| Social circumstances | 1 ( 0.1)  |
| Vascular disorders | 1 (0.1) |
| ***Permanent Discontinuation Due to AE by system organ classes, n (EAIR)***  |  |
| Infections and infestationsa | 42 (4.8) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 9 (1.0) |
| Blood and lymphaticsystem disorders | 8 (0.9) |
| Hepatobiliary disorders | 8 (0.9) |
| Respiratory, thoracic and mediastinal disorders | 6 (0.7) |
| Investigations | 4 (0.5) |
| Nervous system disorders | 2 (0.2) |
| Cardiac disorders | 1 (0.1) |
| Gastrointestinal disorders | 1 (0.1) |
| Injury, poisoning and procedural complications | 1 (0.1) |
| Vascular disorders  | 1 (0.1) |
| Not coded | 1 (0.1) |

For TEAEs and AEs leading to temporary interruption, EAIRs were calculated as the number of unique patients with an event per 100 PY of overall exposure time. For AEs leading to permanent discontinuation, EAIRs were calculated as the number of unique patients with an event per 100 PY of overall exposure time, which included any post-drug follow-up time.

aMost infections due to herpes zoster.

AE, adverse event; Bari, baricitinib; EAIR, exposure-adjusted incidence rate; PY, patient-years; RA, rheumatoid arthritis; TEAE, treatment-emergent AE.